| Sumario: | The article focuses on the evolving landscape of Alzheimer's disease (AD) diagnosis and treatment, particularly the implementation of anti-amyloid therapies like lecanemab within the Veterans Health Administration (VHA). It highlights the shift from clinical diagnosis to biomarker-based confirmation, emphasizing the complexities of diagnosing AD/ADRD due to co-existing conditions. The survey conducted by O'Donnell et al. reveals both facilitators and barriers to implementing lecanemab, including the need for extensive infrastructure and interdisciplinary collaboration. The article underscores the importance of proactive engagement from geriatricians in ensuring safe and effective delivery of these therapies, while also acknowledging the challenges posed by the modest efficacy and safety concerns associated with lecanemab.
|
|---|